Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV.
Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.77 Increased by +45.39% | -1.10 Increased by +30.00% |
| May 2, 24 | -0.62 Increased by +52.31% | -1.24 Increased by +50.00% |
| Feb 20, 24 | -1.16 Decreased by -14.85% | -1.23 Increased by +5.69% |
| Nov 2, 23 | -1.26 Decreased by -31.25% | -1.17 Decreased by -7.69% |
| Aug 3, 23 | -1.41 Decreased by -56.67% | -1.29 Decreased by -9.30% |
| May 4, 23 | -1.30 Decreased by -39.78% | -1.07 Decreased by -21.50% |
| Feb 28, 23 | -1.01 Decreased by -60.32% | -1.06 Increased by +4.72% |
| Nov 3, 22 | -0.96 Decreased by -62.71% | -0.89 Decreased by -7.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 9.37 M Decreased by -17.77% | -39.86 M Increased by +6.45% | Decreased by -425.30% Decreased by -13.77% |
| Mar 31, 24 | 19.52 M Increased by +298.67% | -26.55 M Increased by +32.04% | Decreased by -136.01% Increased by +82.95% |
| Dec 31, 23 | 5.33 M Increased by +67.38% | -49.10 M Decreased by -63.78% | Decreased by -921.01% Increased by +2.15% |
| Sep 30, 23 | 5.35 M Increased by +76.05% | -49.90 M Decreased by -76.03% | Decreased by -932.32% Increased by +0.02% |
| Jun 30, 23 | 11.40 M Increased by +160.32% | -42.60 M Decreased by -58.80% | Decreased by -373.81% Increased by +39.00% |
| Mar 31, 23 | 4.90 M Increased by +26.84% | -39.06 M Decreased by -41.72% | Decreased by -797.88% Decreased by -11.73% |
| Dec 31, 22 | 3.19 M Decreased by -15.54% | -29.98 M Decreased by -66.20% | Decreased by -941.22% Decreased by -96.78% |
| Sep 30, 22 | 3.04 M Decreased by -29.84% | -28.35 M Decreased by -93.13% | Decreased by -932.47% Decreased by -175.27% |